News Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
65.96 ^USD	+2.18%		+8.63%	+5.03%

25/04	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT
22/04	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	26/04	MT
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	23/04	MT
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04	GL
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03	CI
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03	CI
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03	CI
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21/03	MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating	12/03	MT
Transcript : Vaxcyte, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM	12/03
Transcript : Vaxcyte, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	06/03
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	04/03	GL
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03	CI
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating	28/02	MT
Vaxcyte Q4 Loss Widens	28/02	MT
Transcript : Vaxcyte, Inc., Q4 2023 Earnings Call, Feb 27, 2024	28/02
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	28/02	GL
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	16/02	GL
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02	AQ
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Summary

Filters